Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Acquires 1,036 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky bought 1,036 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the acquisition, the chief operating officer owned 1,036 shares of the company’s stock, valued at $49,966.28. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Friday, August 28th, Liane Rae Teplitsky acquired 1,034 shares of Pulse Biosciences stock. The shares were acquired at an average price of $48.35 per share, with a total value of $49,993.90.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $47.57 on Friday. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -40.31 and a beta of 1.61. Pulse Biosciences, Inc has a 1-year low of $12.56 and a 1-year high of $50.90. The company has a 50 day moving average price of $35.38 and a 200 day moving average price of $27.00.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, sell-side analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $28,000. Tower Research Capital LLC TRC grew its holdings in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after acquiring an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Pulse Biosciences in the second quarter worth $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on PLSE. Canaccord Genuity Group upped their price target on shares of Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research note on Monday, August 10th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Finally, Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.